PL2598525T3 - Mutanty frataksyny - Google Patents

Mutanty frataksyny

Info

Publication number
PL2598525T3
PL2598525T3 PL11788225T PL11788225T PL2598525T3 PL 2598525 T3 PL2598525 T3 PL 2598525T3 PL 11788225 T PL11788225 T PL 11788225T PL 11788225 T PL11788225 T PL 11788225T PL 2598525 T3 PL2598525 T3 PL 2598525T3
Authority
PL
Poland
Prior art keywords
frataxin
mutants
frataxin mutants
Prior art date
Application number
PL11788225T
Other languages
English (en)
Inventor
Roberto Testi
Original Assignee
Roberto Testi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Testi filed Critical Roberto Testi
Publication of PL2598525T3 publication Critical patent/PL2598525T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0091Oxidoreductases (1.) oxidizing metal ions (1.16)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y116/00Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/03Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
    • C12Y116/03001Ferroxidase (1.16.3.1), i.e. ceruloplasmin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11788225T 2010-07-28 2011-07-27 Mutanty frataksyny PL2598525T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36857610P 2010-07-28 2010-07-28
EP11788225.8A EP2598525B1 (en) 2010-07-28 2011-07-27 Frataxin mutants
PCT/IB2011/002511 WO2012014083A2 (en) 2010-07-28 2011-07-27 Frataxin mutants

Publications (1)

Publication Number Publication Date
PL2598525T3 true PL2598525T3 (pl) 2016-03-31

Family

ID=45044630

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11788225T PL2598525T3 (pl) 2010-07-28 2011-07-27 Mutanty frataksyny

Country Status (12)

Country Link
US (2) US9217019B2 (pl)
EP (2) EP2598525B1 (pl)
CA (1) CA2806303C (pl)
DK (1) DK2598525T3 (pl)
ES (1) ES2552456T3 (pl)
HR (1) HRP20151238T1 (pl)
HU (1) HUE028111T2 (pl)
PL (1) PL2598525T3 (pl)
PT (1) PT2598525E (pl)
SI (1) SI2598525T1 (pl)
SM (1) SMT201500264B (pl)
WO (1) WO2012014083A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
WO2016103223A1 (en) * 2014-12-23 2016-06-30 Fratagene Therapeutics Ltd. Methods of treating friedreich's ataxia using src inhibitors
US20180021364A1 (en) * 2015-01-16 2018-01-25 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
EP3436006B1 (en) 2016-03-30 2025-07-30 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
EA201990864A1 (ru) * 2016-11-09 2019-11-29 Конструкции для экспрессии фратаксина
US11759533B2 (en) 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
US20200263199A1 (en) 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
US20220378869A1 (en) 2019-07-18 2022-12-01 Larimar Therapeutics, Inc. Use of frataxin for treating leigh syndrome, french canadian type
US12566178B2 (en) 2019-07-29 2026-03-03 Larimar Therapeutics, Inc. Methods of quantifying frataxin and frataxin fusion proteins
EP4004022B1 (en) 2019-07-29 2025-12-31 The Trustees of Indiana University Substances and methods for the treatment of Friedreich's disease
EP4065984A1 (en) 2019-11-25 2022-10-05 Larimar Therapeutics, Inc. Methods for quantifying frataxin activity
KR20230005333A (ko) 2020-04-30 2023-01-09 라리마 테라퓨틱스, 인코포레이티드 미엘린 관련 질환 및 미토콘드리아 관련 질환을 치료하기 위한 방법
US12390509B2 (en) 2020-12-12 2025-08-19 Larimar Therapeutics, Inc. Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2011070444A2 (en) * 2009-12-07 2011-06-16 Roberto Testi Compositions and methods for treating friedreich's ataxia

Also Published As

Publication number Publication date
US9217019B2 (en) 2015-12-22
PT2598525E (pt) 2015-11-02
US20130196932A1 (en) 2013-08-01
US9944906B2 (en) 2018-04-17
EP2598525B1 (en) 2015-08-19
SMT201500264B (it) 2016-01-08
HRP20151238T1 (hr) 2015-12-18
SI2598525T1 (sl) 2016-02-29
ES2552456T3 (es) 2015-11-30
EP3012267A1 (en) 2016-04-27
HUE028111T2 (en) 2016-11-28
CA2806303C (en) 2018-01-02
WO2012014083A3 (en) 2012-04-19
EP2598525A2 (en) 2013-06-05
CA2806303A1 (en) 2012-02-02
DK2598525T3 (da) 2015-09-21
WO2012014083A2 (en) 2012-02-02
US20160060605A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
HRP20181800T1 (hr) Bunar
AP3607A (en) Substituted imidazopyridazines
AP3107A (en) 5-Alkynyl-pyrimidines
PT2598525E (pt) Mutantes de frataxina
PL2534132T3 (pl) Podstawione pirolidyno-2-karboksyamidy
GB201012176D0 (en) Well
GB201021502D0 (en) Biomarkers
GB201008340D0 (en) Biomarkers
GB201018056D0 (en) Biomarkers
IL230217B (en) New mutations ecd–r17–il
ZA201304430B (en) Substituted sodium-1h-pyrazole-5-olate
GB201004442D0 (en) Biomarker
GB201005561D0 (en) Biomarkers
GB201001444D0 (en) Biomarkers
GB201010316D0 (en) Biomarkers
GB201103569D0 (en) Mutants
GB201005456D0 (en) Biomarkers
GB201015267D0 (en) An object forming assembly
EP2588088A4 (en) SOLID SHAPES
GB201001419D0 (en) Biomarkers
GB2487707B (en) Sliding gauge
GB201008727D0 (en) Biomarkers
GB201021504D0 (en) Biomarkers
GB201005563D0 (en) Biomarkers
GB201021498D0 (en) Biomarkers